Teva Pharmaceuticals and Viatris Granted Opportunity to Dispute Johnson & Johnson's Schizophrenia Drug Patent
Monday, 1 April 2024, 16:17
Teva and Viatris Patent Challenge
Teva Pharmaceuticals and Viatris have recently been provided with an opportunity to challenge Johnson & Johnson's patent for a schizophrenia drug.
Implications for the Industry
This new chance could disrupt the pharmaceutical landscape and impact the future of medication patent challenges.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.